The Hyderabad based NATCO Pharma Limited had recorded a jump in its revenues and profits for the year ended on 31st March, 2009.

The Company recorded an increase of 28% in Its consolidated revenues, which have gone up to Rs. 465 Crores from Rs. 364 Crores. The Company’s profit after tax, has also gone up to Rs. 4398 lakhs from Rs. 4052 lakhs, recording an increase of 8%. But for the asset impairment of nearly Rs.3 Crores considered by the Company on account of US business due to global economic slow down, the profit would have been much higher. The growth in profits has been lower on account of expenses on Phase I clinical trials of the new chemical entity being developed by the Company. The Company is in the final stages of Phase I clinical trials for its new chemical entity with multiple oncological indications and intends to undertake Phase II trials shortly.

The Company has continued to maintain its leadership position in respect of Oncology business, which recorded a 23% jump in earnings (from Rs. 79 Crores to Rs. 97 Crores) as compared to last year. The Company has made significant inroads in its efforts to introduce its products in European and US markets and this has been reflected in its Formulations exports, which have grown (from Rs. 14 Crores to Rs. 31 Crores) by nearly 114% over last year.

The Company has already tied up with Lupin Limited for para IV litigation on Fosrenol (Lanthanum Carbonate) of Shire PLC., with Mylan Inc. for Copaxone(Glatiramer Acetate) of Teva and with Dr. Reddy’s Laboratories Limited for a basket of oncology products. The company intends to develop, supply and market its products in collaboration with these companies.

The Company has already declared and paid an interim dividend of Rs. 1.25 per share.